Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma

A. Laganà, D. Perumal, D. Melnekoff, Benjamin Readhead, B. A. Kidd, V. Leshchenko, P. Y. Kuo, J. Keats, M. DeRome, J. Yesil, D. Auclair, S. Lonial, A. Chari, H. J. Cho, B. Barlogie, S. Jagannath, J. T. Dudley, S. Parekh

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Multiple myeloma (MM) is an incurable malignancy of bone marrow plasma cells characterized by wide clinical and molecular heterogeneity. In this study we applied an integrative network biology approach to molecular and clinical data measured from 450 patients with newly diagnosed MM from the MMRF (Multiple Myeloma Research Foundation) CoMMpass study. A novel network model of myeloma (MMNet) was constructed, revealing complex molecular disease patterns and novel associations between clinical traits and genomic markers. Genomic alterations and groups of coexpressed genes correlate with disease stage, tumor clonality and early progression. We validated CDC42BPA and CLEC11A as novel regulators and candidate therapeutic targets of MMSET-related myeloma. We then used MMNet to discover novel genes associated with high-risk myeloma and identified a novel four-gene prognostic signature. We identified new patient classes defined by network features and enriched for clinically relevant genetic events, pathways and deregulated genes. Finally, we demonstrated the ability of deep sequencing techniques to detect relevant structural rearrangements, providing evidence that encourages wider use of such technologies in clinical practice. An integrative network analysis of CoMMpass data identified new insights into multiple myeloma disease biology and provided improved molecular features for diagnosing and stratifying patients, as well as additional molecular targets for therapeutic alternatives.

Original languageEnglish (US)
Pages (from-to)120-130
Number of pages11
JournalLeukemia
Volume32
Issue number1
DOIs
StatePublished - Jan 1 2018
Externally publishedYes

Fingerprint

Multiple Myeloma
Genes
High-Throughput Nucleotide Sequencing
Plasma Cells
Bone Marrow Cells
Neoplasms
Technology
Therapeutics
Research

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma. / Laganà, A.; Perumal, D.; Melnekoff, D.; Readhead, Benjamin; Kidd, B. A.; Leshchenko, V.; Kuo, P. Y.; Keats, J.; DeRome, M.; Yesil, J.; Auclair, D.; Lonial, S.; Chari, A.; Cho, H. J.; Barlogie, B.; Jagannath, S.; Dudley, J. T.; Parekh, S.

In: Leukemia, Vol. 32, No. 1, 01.01.2018, p. 120-130.

Research output: Contribution to journalArticle

Laganà, A, Perumal, D, Melnekoff, D, Readhead, B, Kidd, BA, Leshchenko, V, Kuo, PY, Keats, J, DeRome, M, Yesil, J, Auclair, D, Lonial, S, Chari, A, Cho, HJ, Barlogie, B, Jagannath, S, Dudley, JT & Parekh, S 2018, 'Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma', Leukemia, vol. 32, no. 1, pp. 120-130. https://doi.org/10.1038/leu.2017.197
Laganà, A. ; Perumal, D. ; Melnekoff, D. ; Readhead, Benjamin ; Kidd, B. A. ; Leshchenko, V. ; Kuo, P. Y. ; Keats, J. ; DeRome, M. ; Yesil, J. ; Auclair, D. ; Lonial, S. ; Chari, A. ; Cho, H. J. ; Barlogie, B. ; Jagannath, S. ; Dudley, J. T. ; Parekh, S. / Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma. In: Leukemia. 2018 ; Vol. 32, No. 1. pp. 120-130.
@article{9b86d4936a8c441480eae1c97bba0529,
title = "Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma",
abstract = "Multiple myeloma (MM) is an incurable malignancy of bone marrow plasma cells characterized by wide clinical and molecular heterogeneity. In this study we applied an integrative network biology approach to molecular and clinical data measured from 450 patients with newly diagnosed MM from the MMRF (Multiple Myeloma Research Foundation) CoMMpass study. A novel network model of myeloma (MMNet) was constructed, revealing complex molecular disease patterns and novel associations between clinical traits and genomic markers. Genomic alterations and groups of coexpressed genes correlate with disease stage, tumor clonality and early progression. We validated CDC42BPA and CLEC11A as novel regulators and candidate therapeutic targets of MMSET-related myeloma. We then used MMNet to discover novel genes associated with high-risk myeloma and identified a novel four-gene prognostic signature. We identified new patient classes defined by network features and enriched for clinically relevant genetic events, pathways and deregulated genes. Finally, we demonstrated the ability of deep sequencing techniques to detect relevant structural rearrangements, providing evidence that encourages wider use of such technologies in clinical practice. An integrative network analysis of CoMMpass data identified new insights into multiple myeloma disease biology and provided improved molecular features for diagnosing and stratifying patients, as well as additional molecular targets for therapeutic alternatives.",
author = "A. Lagan{\`a} and D. Perumal and D. Melnekoff and Benjamin Readhead and Kidd, {B. A.} and V. Leshchenko and Kuo, {P. Y.} and J. Keats and M. DeRome and J. Yesil and D. Auclair and S. Lonial and A. Chari and Cho, {H. J.} and B. Barlogie and S. Jagannath and Dudley, {J. T.} and S. Parekh",
year = "2018",
month = "1",
day = "1",
doi = "10.1038/leu.2017.197",
language = "English (US)",
volume = "32",
pages = "120--130",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma

AU - Laganà, A.

AU - Perumal, D.

AU - Melnekoff, D.

AU - Readhead, Benjamin

AU - Kidd, B. A.

AU - Leshchenko, V.

AU - Kuo, P. Y.

AU - Keats, J.

AU - DeRome, M.

AU - Yesil, J.

AU - Auclair, D.

AU - Lonial, S.

AU - Chari, A.

AU - Cho, H. J.

AU - Barlogie, B.

AU - Jagannath, S.

AU - Dudley, J. T.

AU - Parekh, S.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Multiple myeloma (MM) is an incurable malignancy of bone marrow plasma cells characterized by wide clinical and molecular heterogeneity. In this study we applied an integrative network biology approach to molecular and clinical data measured from 450 patients with newly diagnosed MM from the MMRF (Multiple Myeloma Research Foundation) CoMMpass study. A novel network model of myeloma (MMNet) was constructed, revealing complex molecular disease patterns and novel associations between clinical traits and genomic markers. Genomic alterations and groups of coexpressed genes correlate with disease stage, tumor clonality and early progression. We validated CDC42BPA and CLEC11A as novel regulators and candidate therapeutic targets of MMSET-related myeloma. We then used MMNet to discover novel genes associated with high-risk myeloma and identified a novel four-gene prognostic signature. We identified new patient classes defined by network features and enriched for clinically relevant genetic events, pathways and deregulated genes. Finally, we demonstrated the ability of deep sequencing techniques to detect relevant structural rearrangements, providing evidence that encourages wider use of such technologies in clinical practice. An integrative network analysis of CoMMpass data identified new insights into multiple myeloma disease biology and provided improved molecular features for diagnosing and stratifying patients, as well as additional molecular targets for therapeutic alternatives.

AB - Multiple myeloma (MM) is an incurable malignancy of bone marrow plasma cells characterized by wide clinical and molecular heterogeneity. In this study we applied an integrative network biology approach to molecular and clinical data measured from 450 patients with newly diagnosed MM from the MMRF (Multiple Myeloma Research Foundation) CoMMpass study. A novel network model of myeloma (MMNet) was constructed, revealing complex molecular disease patterns and novel associations between clinical traits and genomic markers. Genomic alterations and groups of coexpressed genes correlate with disease stage, tumor clonality and early progression. We validated CDC42BPA and CLEC11A as novel regulators and candidate therapeutic targets of MMSET-related myeloma. We then used MMNet to discover novel genes associated with high-risk myeloma and identified a novel four-gene prognostic signature. We identified new patient classes defined by network features and enriched for clinically relevant genetic events, pathways and deregulated genes. Finally, we demonstrated the ability of deep sequencing techniques to detect relevant structural rearrangements, providing evidence that encourages wider use of such technologies in clinical practice. An integrative network analysis of CoMMpass data identified new insights into multiple myeloma disease biology and provided improved molecular features for diagnosing and stratifying patients, as well as additional molecular targets for therapeutic alternatives.

UR - http://www.scopus.com/inward/record.url?scp=85040831741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040831741&partnerID=8YFLogxK

U2 - 10.1038/leu.2017.197

DO - 10.1038/leu.2017.197

M3 - Article

C2 - 28642592

AN - SCOPUS:85040831741

VL - 32

SP - 120

EP - 130

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 1

ER -